Unknown

Dataset Information

0

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

SUBMITTER: De Laere B 

PROVIDER: S-EPMC6499126 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

De Laere Bram B   Rajan Prabhakar P   Grönberg Henrik H   Dirix Luc L   Lindberg Johan J  

JAMA oncology 20190701 7

Similar Datasets

Unknown <i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC6330086 | biostudies-literature
Unknown Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC11329885 | biostudies-literature
Unknown Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
| S-EPMC7204265 | biostudies-literature
Unknown Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide.
| S-EPMC8864032 | biostudies-literature
Unknown Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
| S-EPMC6118405 | biostudies-literature
Unknown Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan.
| S-EPMC8940330 | biostudies-literature
Unknown Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
| S-EPMC9385484 | biostudies-literature
Unknown Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
| S-EPMC6764911 | biostudies-literature
Unknown The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC12470515 | biostudies-literature
Unknown Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.
| S-EPMC10807645 | biostudies-literature